Paper Details

  1. Home
  2. Paper Details

Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.

Author: , ArgenzianoGiuseppe, AsciertoPaolo Antonio, BianchiLuca, BocchinoEnrico, Calzavara-PintonPiergiacomo, Di StefaniAlessandro, DikaEmi, FabbrociniGabriella, FargnoliMaria Concetta, FavaPaolo, LongoCaterina, ManninoMaria, PellacaniGiovanni, PerisKetty, PiccerilloAlfredo, QuaglinoPietro, ScalvenziMassimiliano, ZalaudekIris

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hedgehog pathway inhibitors (HHIs) are effective and safe for the treatment of advanced basal cell carcinoma (aBCC). In a multicenter observational study of 178 patients, objective response rates were 76.7% (95% CI: 82.3-68.7) for locally advanced aBCC (laBCC) and 33.3% (95% CI: 88.2-1.7) for metastatic BCC (mBCC). Most therapy-related adverse events (AEs) were mild-moderate in severity.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Advanced basal cell carcinoma (aBCC) represents a complex and clinically heterogeneous group of lesions for which curative surgery and/or radiotherapy is unlikely. Systemic therapy with hedgehog pathway inhibitors (HHIs) changed the treatment landscape for this complex patient population...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000531280

データ提供：米国国立医学図書館（NLM）

Hedgehog Pathway Inhibitors for Advanced Basal Cell Carcinoma

Advanced basal cell carcinoma (aBCC) is a challenging form of skin cancer that often requires systemic therapy. This study, like a camel caravan navigating a treacherous mountain range, explores the effectiveness and safety of hedgehog pathway inhibitors (HHIs) in treating aBCC in a real-life setting. The authors analyzed data from a multicenter observational study conducted in Italy to understand the clinical characteristics of aBCC patients and the outcomes of HHI treatment.

HHIs: A beacon of hope for advanced BCC

The study found that HHIs demonstrated significant effectiveness in treating aBCC, particularly for locally advanced BCC. Objective response rates were high, exceeding 70% for sonidegib and 33% for vismodegib. These results, like finding a hidden oasis in the desert of treatment options, offer significant hope for patients facing this complex form of cancer. The study also noted that the majority of patients experienced at least one therapy-related adverse event, emphasizing the importance of carefully monitoring patients during treatment.

Navigating the desert of cancer treatment

This research, like a compass guiding us through the complexities of cancer treatment, provides valuable insights into the effectiveness and safety of HHIs for aBCC. The study highlights the importance of a multidisciplinary approach to cancer care, involving careful patient selection, close monitoring for adverse events, and individualized treatment plans.

Dr. Camel's Conclusion

This research adds to our understanding of HHI treatment for aBCC, highlighting their potential for improving patient outcomes. The study underscores the importance of careful patient selection and ongoing monitoring to ensure the safe and effective use of these medications. While HHIs offer a beacon of hope for patients with aBCC, navigating the desert of cancer treatment requires a thoughtful and collaborative approach to maximize benefits and minimize risks.

Date :
  1. Date Completed 2023-12-07
  2. Date Revised 2023-12-07
Further Info :

Pubmed ID

37311439

DOI: Digital Object Identifier

10.1159/000531280

Related Literature

Article Analysis
・Effects of sonidegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.